GSK Partners with Muna Therapeutics to Unlock Novel Alzheimer’s Treatments

Strategic Alliance:
Muna Therapeutics and GSK have formed a strategic alliance to identify and validate novel drug targets for Alzheimer’s disease treatments123.

MiND-MAP Platform:
The collaboration leverages Muna’s MiND-MAP platform, which applies spatial transcriptomics to analyze post-mortem brain samples from Alzheimer’s disease patients, cognitively resilient individuals, healthy controls, and centenarians with and without cognitive impairment123.

Financial Terms:
Muna will receive an upfront payment of €33.5 million from GSK and is eligible for up to €140 million per target in milestone payments, as well as tiered royalties on net sales of products125.

Collaboration Roles:
Muna will lead the identification and validation of new Alzheimer’s disease targets, while GSK will lead drug development, preclinical activities, clinical development, manufacturing, and commercialization125.

Research Focus:
The alliance aims to uncover the genetic and cellular mechanisms behind Alzheimer’s progression and resilience, with the goal of identifying new therapeutic targets123.

Impact:
The partnership aims to transform the landscape of drug discovery for neurodegenerative diseases and bring new hope to millions of patients worldwide123.

Sources:

1. https://investors.vib.be/vib-spin-off-muna-therapeutics-announces-strategic-alliance-with-gsk-to-accelerate-development-of-novel-treatments-for-alzheimers-disease

2. https://www.biospace.com/press-releases/muna-therapeutics-announces-strategic-alliance-with-gsk-to-accelerate-development-of-novel-treatments-for-alzheimers-disease

3. https://alzheimersnewstoday.com/news/muna-gsk-partner-develop-targets-alzheimers-treatments/

5. https://www.prnewswire.com/news-releases/muna-therapeutics-announces-strategic-alliance-with-gsk-to-accelerate-development-of-novel-treatments-for-alzheimers-disease-302322958.html